RxDoctor Payments DataLook up a doctor →

Matthew Adler, PA

Medical · Brighton, MINPI 1033293659

Payments from drug & device makers

$21,784in general payments, 2019–2025

Across 1,458 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$4K
  • Johnson & Johnson$4K
  • AbbVie$2K
  • Novartis$2K
  • Incyte Corporation$1K
  • Galderma Laboratories, L.p.$1K
  • plus $7K from 24 others

What the payments were for

  • Consulting fees$6503%
  • Speaking & faculty fees$290%
  • Food & beverage$20,09592%
  • Education$1,0115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,784 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$118,200
Medicare patients
471
Services billed
2,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab25$185,059
OtezlaApremilast16$74,804
Clobetasol Propionate126$3,606
Tacrolimus25$2,355
Metronidazole32$1,641
Azelaic Acid11$1,457
Triamcinolone Acetonide123$1,163
Ciclopirox26$849
Ketoconazole59$784
Econazole Nitrate39$695
Mupirocin72$591
Ammonium Lactate19$407
Clindamycin Phosphate20$393
CiclopiroxCiclopirox Olamine20$243
Imiquimod19$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$471$74,80416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.

Other medical in Brighton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →